SEDLine™ Announces Acquisition of Hospira Brain Function Monitoring Business

SEDLine™, Inc., announced today that it has acquired the brain function monitoring business of Hospira, Inc. (NYSE:HSP). Privately held and backed with an investment from Masimo Corporation (NASDAQ:MASI), SEDLine, Inc., based in Irvine, California, was formed with the mission to advance neuromonitoring technologies to improve the care of patients under anesthesia or sedation.

Brain function monitoring (BFM) has become a widely utilized modality for assessing depth of anesthesia and sedation. Based primarily on analysis of the electroencephalogram (EEG), brain function monitors continuously measure the electrical activity of the brain and translate those changes to the level of consciousness. BFM has been deployed in a variety of clinical environments, ranging from the operating room for patients having surgery, to intensive care units where critically ill patients can be sedated for prolonged periods, and in short procedure units where patients undergo procedures such as colonoscopy and endoscopy.

SEDLine’s technology is based on 10 years of innovation and offers a cost-effective alternative to other monitors, while delivering proven 4-channel EEG integrated algorithm performance, demonstrated reliability under challenging clinical conditions and superior resistance to cautery¹.

David E. Goodman, MD, MSE, President & CEO, SEDLine commented, "We are very excited to acquire the SEDLine brain function monitoring platform from Hospira. We intend to continue Hospira’s tradition of providing outstanding support for its customers. To reinforce our commitment to the newly acquired product line, the original Hospira Brain Function Monitoring team has joined SEDLine, Inc., ensuring that we will be able to provide all of the products, service, and support previously received from Hospira.”

Joe E. Kiani, Founder, Chairman and CEO of Masimo Corporation, commented, "We are happy to be able to provide an investment in SEDLine to help it advance and improve brain function monitoring for patients under anesthesia and sedation. Their clear commitment to invest in R&D as well as to offer excellent customer care resonates well with Masimo, and we wish them great success as they launch their new company.”

Financial details of the agreement were not disclosed.

About SEDLine

SEDLine, Inc. is a research-focused company with the mission to expand the scope and applications for neuromonitoring. Based on over 10 years of technical and clinical development, the SEDLine core product is a pioneering four-channel brain-function monitor that measures the effects of anesthesia and sedation by simultaneously analyzing, quantifying and displaying both sides of the brain’s electrical activity. The SEDLine monitor is currently in use at some of the nation’s leading healthcare institutions. Privately held and based in Irvine, California, SEDLine has an active R&D effort underway to develop advanced brain function monitoring technologies for next generation monitors to further improve the care of patients under anesthesia or sedation. Additional information about SEDLine may be found at www.sedline.com.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees. Learn more at www.hospira.com.

About Masimo

Masimo (NASDAQ:MASI) develops innovative monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET^®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO₂ and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET^® Pulse CO-Oximetry^TM, a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET Pulse CO-Oximetry continuously and noninvasively measures total hemoglobin (SpHb^TM), oxygen content (SpOC^TM), carboxyhemoglobin (SpCO^®), methemoglobin (SpMet^®), PVI^®, in addition to oxyhemoglobin (SpO₂), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. In 2009, Masimo introduced Rainbow SET Acoustic Monitoring, offering continuous and noninvasive respiration rate (RRa^TM) from an innovative acoustic sensor applied to the patient’s neck. Rainbow Acoustic Monitoring is accurate, easy-to-use, and enhances patient compliance – which may help clinicians detect respiratory compromise and patient distress earlier and offer a breakthrough in patient safety. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com.

SEDLine, Masimo, Hospira, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, RRa, Radical-7, Rad-87, Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of their respective companies.

¹ White PF, Tang J, Ma H, Wender RH, Sloninsky A, Kariger R . Is the Patient State Analyzer with the PSArray2 a cost-effective alternative to the Bispectral Index Monitor during the perioperative period? Anesth Analg. 2004;99:1429-1435.